Timothy Kelley
MANAGED CARE December 1997. ©1997 Stezzi Communications

Timothy Kelley

I wince when I recall the first opinion column of mine that ever saw print. It was in the University of Chicago's student newspaper, the Maroon, and it admonished left-leaning students about the habit some of them had of using an extreme-right political label as a casual term of disapprobation. It was just as unfair, I meant to suggest, for them to castigate foes loosely as "fascists" as it was for others to find a "commie" under every couch. One line of undergraduate eloquence sticks relentlessly in my mind: "Fascist," I declared, "is a word with a fairly strong sting to it."

This was in 1968, when some students around the world were up to a good deal more than ill-chosen rhetoric. My column came off rather preachy, and the fact that it was accompanied by an unfortunate photograph (not enough shadow?) made the whole episode embarrassing. I'd be in the dormitory dining hall minding my business when the conversation around me would take a certain turn and one young sarcastic intellectual would say to another, "Uh-oh, that's name-calling. Kelley won't approve." At which point it was incumbent on me in the name of good sportsmanship to snarl back, "Shut up, you fascist!"

So it is with some trepidation that I take up my editorial pen once again to bemoan an unwarranted instance of guilt-by-association rhetoric. I refer to the yeoman service the Clinton Health Reform Plan is rendering these days — not in its intended function, of course, but as an all-purpose bugaboo. Anyone who even whispers of assigning some new health care function to the federal government hears his idea dismissed contemptuously by its opponents as the return of the Big Bad Clinton Plan. (See Washington Initiatives for one example.) Is it too much to hope that, at least until they reach 1,300 pages, new proposals can be judged on their own merits and not by such cynical demonizing?

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.